
    
      Open-label,non-controlled study design with three visits (pre-treatment/baseline, treatment
      day 14 and day 28). Administered Esarin Gel twice daily for 28 days in subjects with chronic
      venous insufficiency rated between CEAP 0 and 3 or varicose veins combine superficial vein
      thrombophlebitis, in comparison to the pre-treatment.
    
  